indinavir-sulfate and Lip-Diseases

indinavir-sulfate has been researched along with Lip-Diseases* in 1 studies

Trials

1 trial(s) available for indinavir-sulfate and Lip-Diseases

ArticleYear
Effect of indinavir on the single-dose pharmacokinetics of theophylline in healthy subjects.
    Journal of clinical pharmacology, 1999, Volume: 39, Issue:6

    The effect of multiple doses of indinavir on the pharmacokinetics of a single dose of theophylline was investigated in 16 healthy male subjects using a randomized, double-blind, placebo-controlled, parallel-group study design. On days 1 and 7, all of the subjects received a single oral 250 mg dose of theophylline. From days 2 to 7, the subjects received orally administered 800 mg doses of indinavir or a matched placebo every 8 hours. On day 7, theophylline and indinavir (or a placebo) were coadministered. The geometric mean AUC(0-24 h) of theophylline increased 18% when coadministered with indinavir compared to when theophylline was administered alone. This small increase in AUC(0-24 h), although considered statistically significant, did not meet the prespecified criterion for clinical significance. The geometric mean Cmax of theophylline, when coadministered with indinavir, was within 8% of theophylline when administered alone. The mean tmax (+/- SD) value for theophylline, when coadministered with indinavir (0.9 +/- 0.5 h), was comparable to that observed for theophylline alone (1.0 +/- 0.5 h). In conclusion, the administration of multiple doses of indinavir followed by a single dose of theophylline did not appear to result in a clinically significant pharmacokinetic interaction for theophylline.

    Topics: Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Area Under Curve; Bronchodilator Agents; Dizziness; Double-Blind Method; Drug Interactions; Humans; Indinavir; Lip Diseases; Male; Middle Aged; Theophylline

1999